Equillium (EQ) Expected to Announce Earnings on Wednesday

Equillium (NASDAQ:EQ) is expected to be posting its Q3 2025 results before the market opens on Wednesday, November 12th. Analysts expect Equillium to post earnings of ($0.14) per share for the quarter. Individuals may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Tuesday, November 11, 2025 at 4:00 PM ET.

Equillium (NASDAQ:EQ) last released its earnings results on Thursday, August 14th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). On average, analysts expect Equillium to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Equillium Stock Down 7.1%

NASDAQ:EQ opened at $1.44 on Wednesday. The business’s 50-day moving average price is $1.53 and its 200 day moving average price is $0.87. The firm has a market cap of $85.68 million, a P/E ratio of -2.57 and a beta of 1.57. Equillium has a 52-week low of $0.27 and a 52-week high of $2.35.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. Wall Street Zen raised Equillium to a “sell” rating in a report on Friday, September 5th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Equillium in a report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Reduce” and an average target price of $1.00.

About Equillium

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.